Advertisement

Topics

Novo-Metacrine deal aims to advance FGF1 variants for diabetes

05:50 EDT 17 Aug 2017 | SmartBrief

Novo Nordisk and Metacrine agreed to work together in an effort to advance fibroblast growth factor 1 variants for glucose lo -More

Original Article: Novo-Metacrine deal aims to advance FGF1 variants for diabetes

NEXT ARTICLE

More From BioPortfolio on "Novo-Metacrine deal aims to advance FGF1 variants for diabetes"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...